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Abstract 
Anti-CRISPRs (Acrs) are small proteins that inhibit the RNA-guided DNA targeting activity of 
CRISPR-Cas enzymes. Encoded by bacteriophage and phage-derived bacterial genes, Acrs 
prevent CRISPR-mediated inhibition of phage infection and can also block CRISPR-Cas-
mediated genome editing in eukaryotic cells. To identify Acrs capable of inhibiting 
Staphylococcus aureus Cas9 (SauCas9), an alternative to the most commonly used genome 
editing protein Streptococcus pyogenes Cas9 (SpyCas9), we used both self-targeting CRISPR 
screening and guilt-by-association genomic search strategies. Here we describe three new potent 
inhibitors of SauCas9 that we name AcrIIA13, AcrIIA14, and AcrIIA15. These inhibitors share a 
conserved N-terminal sequence that is dispensable for DNA cleavage inhibition, and have 
divergent C-termini that are required in each case for inhibition of SauCas9-catalyzed DNA 
cleavage. In human cells, we observe robust inhibition of SauCas9-induced genome editing by 
AcrIIA13 and moderate inhibition by AcrIIA14 and AcrIIA15. We also find that the conserved 
N-terminal domain of AcrIIA13-15 binds to an inverted repeat sequence in the promoter of these 
Acr genes, consistent with its predicted helix-turn-helix DNA binding structure. These data 
demonstrate an effective strategy for Acr discovery and establish AcrIIA13-15 as unique 
bifunctional inhibitors of SauCas9. 
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Significance Statement 
Many mobile genetic elements contain anti-CRISPRs (Acr) to evade host CRISPR defenses. 
Acrs have been discovered that inhibit therapeutically relevant CRISPR-Cas gene editors such as 
Cas12 and Cas9, including many inhibitors for Streptococcus pyogenes Cas9 (SpyCas9). 
However, there are few inhibitors known for the Cas9 from Staphylococcus aureus (SauCas9), 
which is both highly active in human cells and easier to deliver than SpyCas9 due to its smaller 
size. In this work, we search within Staphylococcus genomes for Acrs able to inhibit SauCas9. 
We discover three new Acrs (AcrIIA13, AcrIIA14, AcrIIA15) and demonstrate all three are able 
to inhibit CRISPR-Cas9 gene editing. Our findings highlight the utility of our Acr search method 
for finding Acrs against specific Cas nucleases. 
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Introduction 
CRISPR systems are RNA-guided, adaptive immune systems that defend prokaryotes against 
invading mobile genetic elements (MGEs) (1). However, some MGEs, particularly phages, have 
evolved anti-CRISPRs (Acrs), peptide inhibitors of Cas proteins that block CRISPR defense 
systems (2, 3). Acrs have been discovered to inhibit distinct CRISPR systems, including type I 
(4-8), type II (9-16), type III (17, 18), and type V (7, 19). Strategies for identifying new Acrs 
include testing genes of unknown function that are proximal to anti-CRISPR associated (aca) 
genes (5-7, 9, 15) and screening genes in organisms with self-targeting CRISPR systems (7, 19).  
The frequent clustering of Acr and aca genes together allows for a ‘guilt-by-association’ 
approach that quickly identifies potential Acr candidates for experimental testing, but requires a 
known Acr or aca gene to seed the search (5-7, 9, 15). Conversely, self-targeting CRISPR 
systems are present in diverse genomes that could encode corresponding CRISPR-Cas inhibitors 
to block autoimmunity (20) (Fig. 1A), but finding relevant Acr-encoding genes within these 
genomes can be daunting. Nonetheless, analysis of known Acrs suggests that self-targeting 
CRISPR-containing genomes are attractive to study because they often encode at least one 
corresponding Acr (19). 
Multiple anti-CRISPR (Acr) families inhibit Streptococcus pyogenes Cas9 (SpyCas9) and 
various Cas12a proteins, and can be used in cell-based experiments to control genome editing 
outcomes (7, 10, 11, 13, 14, 21, 22). Although weak cross-reactivity with other non-cognate 
Cas9 orthologs has been detected for a subset of these (10, 11, 23), we wondered whether more 
potent inhibitors for a wider selection of particular Cas9 variants might exist in nature. To 
address this question, we focused on Staphylococcus genomes that might encode inhibitors of 
Staphylococcus aureus Cas9 (SauCas9), a genome editing alternative to SpyCas9 whose smaller 
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size could offer advantages for delivery into mammalian cells (24, 25). We used a combination 
of self-targeting CRISPR screening and guilt-by-association genomic searches to discover three 
new peptide inhibitors of SauCas9. We show that these SauCas9 Acrs, AcrIIA13, AcrIIA14, and 
AcrIIA15, limit or prevent RNA-guided DNA cleavage in vitro and genome editing in human 
cells. These three inhibitors share a common N-terminal domain with a predicted helix-turn-helix 
structure that is dispensable for DNA-cleavage inhibition but can bind specifically to the inverted 
repeat sequence in the promoter of these Acr genes. The C-terminus of each Acr is distinct and is 
responsible for SauCas9 inhibition in each case, likely by differing mechanisms. These SauCas9 
inhibitors provide new tools for the selective control of genome editing outcomes, and validate a 
multi-pronged strategy for discovering diverse Acrs in nature.  
 
Results 
Bioinformatic identification of self-targeting type II-A CRISPR systems 
To identify potential new Acrs that inhibit SauCas9, we first used the Self-Target Spacer 
Searcher (STSS) (19) to query all Staphylococcus species deposited in NCBI for instances of 
CRISPR self-targeting. We observed 99 total instances of self-targeting in Staphylococcus 
CRISPR systems across 43 different strains out of a potential 11,910 assemblies searched (SI 
Appendix, Dataset S1). Of the 99 self-targeting instances predicted, 50 could not be attributed to 
any particular CRISPR subtype, 48 were associated with a type II-A system, and one occurred as 
part of a type III-A system. We did not observe any self-targeting CRISPR type I-C systems that 
are occasionally found in Staphylococcus (26). It should also be noted that 29 of the predicted 
CRISPR self-targeting systems occurred in eight species whose CRISPR loci were manually 
annotated as type II-A based on identity to other type II-A Cas9-encoding genes. 
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To select the genomes most likely to contain Acrs, we filtered the list of 48 self-targets to 
exclude those with target protospacer-adjacent motifs (PAMs) that were more than one 
indel/mutation away from the known 3′-NNGRR(T) PAM for SauCas9 (25). This step 
eliminated genomes in which an incorrect PAM sequence could explain survival without the 
need for Acrs. The remaining 14 self-targeting instances, belonging to 12 different strains (SI 
Appendix, Dataset S1), were ranked according to similarity of their encoded Cas9 and SauCas9 
(SI Appendix, Table S1). Of the seven Cas9s displaying high similarity to SauCas9 (>50% 
identity with blastp), two species, Staphylococcus haemolyticus and Staphylococcus schleiferi, 
were selected for further screening for Acrs active against SauCas9 based on strain availability. 
 
Self-targeting screen for Acr activity 
To reduce the sequence space to search for Acr genes, we selected only one of the two self-
targeting strains identified for each species (S. schleiferi and S. haemolyticus), since the two 
strains of each respective species contained highly similar genomic sequences and MGE content. 
The S. schleiferi strain 5909-02 was chosen for having three self-targets vs. the two self-targets 
present in strain 2713-03, and S. haemolyticus strain W_75, containing a single self-target, was 
selected arbitrarily over strain W_139 (SI Appendix, Fig. S1).  
To first assess whether the CRISPR systems in S. schleiferi and S. haemolyticus are 
active, we generated amplicons encoding the Cas9, Cas1, Cas2 and Csn2 of each system under 
their natural promoters and a plasmid expressing a single-guide RNA (sgRNA) for SauCas9 (27). 
Two versions of the sgRNA were designed, one targeting a superfolder GFP reporter (sfGFP) 
and the other containing a non-targeting sequence. We co-expressed each amplicon with the 
targeting or control sgRNA-encoding plasmid, and a plasmid encoding sfGFP, in a cell-free 
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transcription-translation extract (TXTL; Fig. 1B) (19, 23). We observed a strong reduction in 
sfGFP expression in the TXTL reaction mixtures expressing the targeting, but not the non-
targeting, sgRNAs (Fig. 1C). This result suggests that the native type II-A CRISPR systems in 
both S. schleiferi strain 5909-02 and S. haemolyticus strain W_75 are active.  
Nearly all currently known Acrs can be found in MGE sequences, especially phages, 
highlighting their use as a CRISPR counter-defense mechanism (3). Therefore, we examined the 
genomes of both S. schleiferi and S. haemolyticus for integrated MGEs using PHASTER (28) 
and Islander (29) to identify potential hotspots that might harbor Acrs. We found four predicted 
MGEs in S. schleiferi strain 5909-02 and eight in the contigs of the S. haemolyticus strain W_75 
assembly. We then designed 27 genome fragment (GF) amplicons in total covering all the 
predicted sequences, each up to ~10 kb, with the goal of best capturing complete operons 
wherever possible (SI Appendix, Table S2). We then prepared TXTL reactions containing DNA 
encoding the sfGFP reporter, the sgRNA-encoding plasmid, a GF amplicon, and the associated 
Cas protein-encoding amplicon from the GF’s source organism. By comparing GFP expression 
over time, we found that the presence of GF5 from S. schleiferi corresponded to nearly complete 
inhibition of Cas9-mediated sfGFP knockdown (Fig. 2A). We observed no inhibitory activity in 
the presence of any GFs derived from S. haemolyticus. 
S. schleiferi GF5 contains eight genes (Fig. 2B), most of which are predicted to be part of 
the lactose metabolic pathway. Genes 1 and 2, however, have no predicted function. We cloned 
each gene from GF5 into a heterologous plasmid under the control of a pTet promoter and then 
used the TXTL assay to test each individual gene for its ability to inhibit SauCas9 expressed 
from a plasmid. We observed that gene 2 alone produced the inhibitory effect previously 
observed with the complete GF5 (Fig. 2C). This gene was named AcrIIA13 to indicate its 
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inhibition of a CRISPR type II-A system, in accord with standard Acr nomenclature (22). There 
is also a homologous protein, AcrIIA13a, found within GF8, and although no inhibitory activity 
from GF8 was ever observed, when AcrIIA13a is expressed separately using the pTet expression 
plasmid, it does exhibit inhibitory activity against SauCas9 (Fig. 2D).  
 
‘Guilt-by-association’ identification of SauCas9 Acrs  
We wondered whether AcrIIA13 or the neighboring gene in its operon (GF5 gene 1) might be 
associated with other Acrs, and whether these inhibitors might have the ability to block activity 
of the SauCas9 protein. We first searched AcrIIA13 homologs to find potential Acr candidates 
co-occurring with it (SI Appendix, Fig. S2A). While we did find a truncated homolog missing 
the AcrIIA13 N-terminus, AcrIIA13b, we did not observe any new genes commonly found near 
AcrIIA13. However, when we searched for homologs of GF5 gene 1, we found that they occur 
widely in bacteria (SI Appendix, Fig. S2B), a typical hallmark of aca genes (6, 9, 10, 15). We 
identified genes that frequently co-occur with GF5 gene 1 and selected them as an initial set of 
Acr candidates. Then, because many Acrs are clustered together, we also added genes that co-
occurred with the initially chosen Acr candidates to create the final test set. This set of ten 
candidate Acr genes was cloned into the pTet expression plasmid for further analysis (SI 
Appendix, Table S3). 
Each of the ten new candidate Acr genes was tested in the TXTL sfGFP depletion 
experiment, using SauCas9 expressed from a recombinant plasmid. After ten hours, we observed 
that TXTL reaction mixtures for two of the new Acr candidates, candidate 1 and candidate 10, 
expressed GFP levels that were significantly higher than the GFP levels observed when no Acr 
candidate was present (Fig. 2E and SI Appendix, Fig. S3). Candidate 1, hereafter referred to as 
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AcrIIA14, is phylogenetically associated with a close homolog of GF5 gene 1 and occurs in 
Staphylococcus simulans strain 19, which had previously passed the PAM filtering step for self-
targeting Staphylococcus genomes and has a Cas9 closely related to SauCas9 (86% identical via 
blastp) (SI Appendix, Table S1). Although candidate 10, hereafter referred to as AcrIIA15, does 
not occur in a CRISPR-self-targeting strain, a close homolog (80% identical via blastp) can be 
found in S. pseudintermedius strain 104N, which is self-targeting (SI Appendix, Fig. S2 and 
Dataset S1).  
 
Reconstitution of Acr activity against SauCas9 
To examine the inhibitory activity detected in the TXTL experiments with AcrIIA13-15, we 
purified each Acr protein and tested its ability to inhibit SauCas9-mediated double-stranded 
DNA (dsDNA) cleavage in vitro. We began by first assembling the SauCas9-sgRNA RNP 
complex, then added the individually purified Acr proteins and dsDNA target. Under these 
conditions, we observed near total inhibition of SauCas9 dsDNA cleavage at 20-fold molar 
excess of Acr relative to Cas9 RNP (Fig. 3A, left and SI Appendix, Fig. S4A, top). To verify that 
the inhibition we observed was not an artifact due to nonspecific binding at high Acr protein 
concentrations, we also performed the cleavage assays in the presence of AcrVA4 and BSA, and 
observed no difference in cleavage activity of SauCas9 in the presence of either BSA or AcrVA4 
(SI Appendix, Fig. S4B). To determine the stage at which the Acrs are able to inhibit SauCas9 
activity, we performed the SauCas9 in vitro cleavage experiments again, but added the Acr 
proteins before the addition of sgRNA. Adding the Acr protein before the sgRNA led to ~4-fold 
increase in inhibition by the Acr proteins, on par with the only currently known broad spectrum 
Acr for type II-A Cas9, AcrIIA5 (11, 30) (Fig. 3A right and SI Appendix, Fig. S4A, bottom). 
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The addition of BSA or AcrVA4 before RNP formation had no effect on cleavage of the target 
(SI Appendix, Fig. S4C). 
We then performed RNA electrophoretic mobility shift assays (EMSA) to determine if 
the Acrs were able to prevent, or reverse, Cas9-sgRNA RNP formation. While AcrIIA13 and 
AcrIIA14 did not prevent RNP formation, the addition of AcrIIA15 before the sgRNA during 
complex formation eliminated the presence of the slow-migrating species corresponding to Cas9 
RNP that is visible when the Acr is added after RNP complex formation (Fig. 3B). The lack of a 
mobility-shifted species when AcrIIA15 is added before sgRNA suggests that AcrIIA15 binds 
directly to Cas9 to prevent RNP formation rather than causing RNP disassembly. Next, we 
performed EMSAs to evaluate the ability of the Acrs to prevent binding of the Cas9-sgRNA 
RNP to its target dsDNA. We found that both AcrIIA13 and AcrIIA15 inhibited dsDNA binding 
of Cas9, but only when added prior to the addition of target dsDNA. Interestingly, although 
AcrIIA14 completely inhibited Cas9 cleavage activity (Fig. 3A), it did not prevent Cas9 RNP 
from binding to its target. However, a super-shifted species was observed after the addition of 
AcrIIA14, either before or after addition of dsDNA. This suggests that AcrIIA14 may act by 
binding the SauCas9 active site without impacting DNA binding, similar to the behavior of 
AcrIIC1 (31). AcrIIA14 might also trigger complex dimerization to form an inactive 
conformation, similar to the mechanisms of AcrIIC3 (31, 32) or AcrVA4 (33) (Fig. 3C). 
Altogether, these biochemical data suggest that each of the newly discovered Acrs inhibits 
SauCas9-mediated DNA cleavage by a different method. 
 
AcrIIA13-15 share a N-terminal domain that is dispensable for cleavage inhibition 
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To determine the level of sequence similarity between AcrIIA13-15, we performed a multiple 
sequence alignment with MUSCLE and observed a shared N-terminal domain across all three 
Acrs, which was absent in AcrIIA13b, a truncated homolog of AcrIIA13 found during the guilt-
by-association search (SI Appendix, Fig. S2B). The remaining C-terminus, however, was not 
closely related between AcrIIA13-15 (SI Appendix, Fig. S5A). Given the apparently distinct 
mechanisms of inhibition for AcrIIA13-15, we suspected that the residues downstream of the 
shared N-terminus were responsible for the Acr activity. To test this, we cloned, expressed and 
purified truncated versions of all three Acrs with the shared N-termini removed (SI Appendix, 
Fig. S5A). In DNA cleavage assays with the purified C-terminal AcrIIA13-15 proteins, all the 
Acrs showed complete inhibition of Cas9 cleavage activity at ~5-fold molar excess whether 
added before or after Cas9-sgRNA RNP formation (Fig. 3D). We also observe strong inhibition 
with the C-terminal portion of AcrIIA13 in the TXTL sfGFP expression assay, while no 
inhibition was detected using the N-terminal domain alone (SI Appendix, Fig. S5B). Overall, 
these data support the conclusion that the variable C-terminal domains of AcrIIA13-15 constitute 
the Acr activity of each protein. We also tested the truncated AcrIIA13-15 proteins for inhibition 
of SpyCas9 in an RNA-guided DNA cleavage assay, but observed no significant reduction in 
DNA cutting (SI Appendix, Fig. S5C). 
 
The shared Acr N-terminal domain binds an inverted-repeat DNA sequence 
On further sequence analysis of the homologous N-terminal section of AcrIIA13-15 using 
HHpred (34), we found they contain a conserved helix-turn-helix (HTH) motif (Fig. 4A and SI 
Appendix, Fig. S5A). HTH domains have been found in aca genes and were recently shown to 
repress their own transcription along with other Acrs in the same operon (16, 35). These aca 
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genes encode proteins that bind to promoter-proximal sequences containing two inverted repeats 
to block polymerase access. Upstream of the operons containing AcrIIA13-15, we observe 
inverted repeats (IR) proximal to the expected promoter sequences for these operons based on 
sequence similarity to the E. coli σ70 consensus promoter (TTGACA-N17-TATAAT) (Fig. 4B). 
To determine if AcrIIA13-15 are capable of binding to the promoter proximal IR sequences, we 
performed DNA EMSAs, combining each purified Acr protein with a FAM-labelled dsDNA 
sequence spanning the IRs in the promoter-proximal region of AcrIIA15 (Fig. 4C). We found 
that AcrIIA13 and AcrIIA15 strongly interact with the promoter-proximal IR sequence, while 
AcrIIA14 only weakly interacted with it (Fig. 4D). Mutating the IR sequence of the dsDNA 
substrate completely abolished the Acr-IR DNA interaction (SI Appendix, Fig. S4E). To further 
assess if this interaction was mediated by the HTH motif, we repeated the DNA EMSA using the 
C-terminal AcrIIA15, and failed to detect any interaction with the dsDNA IR-DNA substrate. 
Together, these data suggest that, similar to AcrIIA1 (16), AcrIIA13-15 also are fusion proteins 
that link an anti-SauCas9 Acr with a DNA binding domain that is likely to regulate the 
expression of its own operon. 
 
Inhibition of SauCas9-mediated genome editing in human cells 
To assess the ability of AcrIIA13-15 to inhibit genome editing in the context of human cells, we 
designed a lentiviral validation system to express Cas9, an sgRNA, and an Acr protein from 
three different, stably integrated constructs (Fig. 5A). Using HEK-RT1 genome editing reporter 
cells (36, 37) - a monoclonal HEK293T-based cell line expressing a doxycycline-inducible GFP 
reporter - lentiviral constructs encoding the AcrIIA proteins or mTagBFP2, and SauCas9 or 
SpyCas9, were sequentially transduced and stable integrants selected. The resulting cell lines 
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were then further transduced with a vector expressing a GFP-targeting or negative control 
sgRNA and an associated mCherry fluorescence marker. In this system, we observed a baseline 
of ~75% GFP-positive cells after induction in presence of a negative control sgRNA, which was 
reduced to near 0% by an on-target sgRNA disrupting GFP expression (SI Appendix, Fig. S6).  
We next tested three known Acrs for their ability to inhibit SauCas9-mediated genome 
editing in mammalian cells, including the robust SpyCas9 inhibitor AcrIIA4 (10), the broad-
spectrum type II-A Cas9 inhibitor AcrIIA5 (12, 30) and the species-specific Streptococcus 
thermophilus Cas9 inhibitor AcrIIA6 (12). While AcrIIA4 prevented genome editing by 
SpyCas9 as expected (10), we found that it had no effect against SauCas9 (SI Appendix, Fig. 
S7). Conversely, AcrIIA5 displayed strong inhibitory activity towards both SauCas9 and 
SpyCas9, as recently shown (30), while AcrIIA6 did not show any inhibition of either of the two 
Cas9s.  
Similar genome editing inhibition experiments using AcrIIA13-15 showed that AcrIIA13 
is a potent inhibitor of SauCas9, with near complete inhibition of GFP gene editing activity (Fig. 
5B and SI Appendix, Fig. S8). However, in contrast to AcrIIA5, AcrIIA13 did not inhibit 
SpyCas9, making it the first Acr selective for SauCas9 to our knowledge, and further expanding 
the CRISPR-Cas modulation toolkit. Interestingly, the truncated form of AcrIIA13, which is 
substantially smaller, was equally effective at inhibiting SauCas9-mediated genome editing in 
human cells. The AcrIIA13b homolog that lacks the N-terminal DNA-binding domain showed a 
comparable trend of SauCas9 selective inhibition. Full-length AcrIIA14 also proved to be a 
potent inhibitor of SauCas9, although less robust than AcrIIA13, and removing its N-terminal 
domain had a larger impact on its inhibitory efficacy (Fig. 5C). SpyCas9 was not affected by 
AcrIIA14. Finally, only AcrIIA15 demonstrated any activity toward SpyCas9-mediated genome 
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editing, but its inhibition was minimal (Fig. 5C), showing that AcrIIA13-15 are potent and 
selective inhibitors for SauCas9.  
 
Discussion 
The potential role of anti-CRISPRs in regulating CRISPR-Cas gene editing in therapeutic 
applications has helped spur the discovery of over 40 different families of Acrs (3). However, 
creating ‘designer’ inhibitors for specific gene editors and editing scenarios is very challenging 
as Acr proteins are small and lack any sequence and structural conservation to use for direct 
identification of desired modalities. One method to overcome these limitations is to cast a wide 
net in the genomic space, such as through metagenomic DNA screening (13, 14). However, 
coverage is a challenge in these screens, as Mb of DNA need to be sifted through to find rare Acr 
genes. The selection of self-targeting genomes (7, 10, 19) is meant to address this issue by 
narrowing screening efforts to only a few candidate genomes. We further focus our search efforts 
to MGEs only, where nearly all Acrs have been discovered (2), reducing the search space to a 
few hundred kb or less. Identifying self-targeting events is particularly powerful when searching 
for specific Acrs against a Cas protein of interest (especially in organisms with multiple CRISPR 
systems), because the search inherently identifies which Cas system is likely being inhibited. 
Yet, an even more direct method is to use a ‘guilt-by-association’ search approach, which 
leverages the repeated observations that Acrs tend to co-exist in similar operons and that the 
genomic neighborhood of several Acrs contain anti-CRISPR associated (aca) genes that are 
closely coupled with Acrs, and widespread in bacteria and MGEs.  
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  In this work, we sought to identify potent inhibitors of SauCas9, a common SpyCas9 
alternative. Using a combination of the methods described above, we identified three novel 
families of Acrs (AcrIIA13-15) that are potent inhibitors of SauCas9. Using biochemical 
approaches, we find that all three Acrs possess different mechanisms of Cas9 inhibition. 
AcrIIA13 prevents SauCas9-mediated dsDNA cleavage activity by blocking DNA binding, 
while AcrIIA15 binds to SauCas9 to block RNP assembly (Figs. 3B, 3C). Our data also show 
that AcrIIA14 does not interfere with SauCas9 binding to either RNA or dsDNA, but inhibits 
dsDNA cleavage activity at a potency comparable to AcrIIA13 and AcrIIA15. It is possible that 
AcrIIA14 either causes the SauCas9-sgRNA RNP to form higher order structures like AcrVA4 
(33) or AcrIIC3 (31, 32), or interacts with RNP to prevent cleavage but not binding like AcrIIC1 
(31). We also observed potent inhibition of SauCas9, but not SpyCas9, by AcrIIA13 and 
AcrIIA14 in mammalian cells (Fig. 5), suggesting both have a narrow range of inhibition. 
AcrIIA15 was able to inhibit both SpyCas9 and SauCas9 in human cells, but to a much lesser 
extent. Of the three Acrs, AcrIIA13 was the most potent inhibitor of SauCas9 in human cells. 
  In comparing the protein sequences between AcrIIA13-15, we observe that the N-termini 
of the Acrs possessed a highly conserved HTH motif (Fig. 4A and SI Appendix, Fig. S5A). This 
motif is a prominent feature of aca genes, which were recently shown to negatively regulate the 
transcription of their own operon (16, 35). The self-regulating activity of aca proteins was shown 
to be mediated by a direct interaction between the HTH motif and promoter proximal sequences 
containing two inverted repeats (IR). Examining the promoter regions of AcrIIA13-15, we found 
that all of them also contain similar promoter-proximal IR sequences (Fig. 4B), and that all three 
Acrs are able to bind to the IR sequences specifically and only when the N-terminal domain is 
present (Fig. 4E). The DNA binding activity of the N-terminal region also has little to no effect 
16 
 
on Acr potency when removed from the protein in in vitro cleavage assays (Fig. 3D and SI 
Appendix, Fig. S5B) and only a minor effect, or none, in human cells depending on the Acr (Fig. 
5B-C). AcrIIA13 in particular is unaffected by the removal of its N-terminus, and represents a 
highly potent, SauCas9-specific inhibitor for use in mammalian contexts for regulating Cas9 
activity. 
  Based on our data, the AcrIIA13-15 proteins we identified are likely fusions between 
each of three unique Acr proteins and a shared aca gene in the form of an Acr gene that inhibits 
Cas9 with an aca gene fused to the N-terminus that is dispensable for DNA cleavage inhibition. 
It is unclear how such an aca gene would have become fused with different Acr proteins, or what 
benefit a single protein would have over the split alternative. Regardless, the new aca gene 
sequence provides another seed to search for further discoveries using the guilt-by-association 
approach. With the addition of yet more proteins, we increase the chances of finding new 
activities that are particularly attractive to biotechnology and therapeutic applications, such as 
catalytic Acrs that would have low delivery requirements for potent inhibition (38, 39). We 
believe that the search for more Acrs with potent and novel mechanisms of inhibition will 
continue to rapidly add new dimensions of control into the CRISPR toolbox. 
 
Materials and Methods 
Self-targeting strain selection. The bioinformatics search for self-targeting Staphylococcus 
strains was carried out in a similar manner as described in Watters, et al. (19). Briefly, the Self-
Targeting Spacer Searcher (STSS) was used the NCBI database for all assemblies returned using 
a search of “Staphylococcus[organism] NOT phage NOT virus”. Each assembly was checked for 
instances of self-targeting, which were reported along with details about the instance including: 
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target site mutations, up/downstream target sequences, Cas genes found near the array of the 
self-targeting spacer, predicted CRISPR subtype based on repeats/Cas proteins, repeat sequences 
and conservation, etc. Systems that were output as ambiguous type II CRISPR systems were 
manually checked for: 1) repeat sequence similarity to other known loci, 2) presence of defining 
Cas proteins (i.e. Csn2 for II-A), and 3) alignment of Cas9 of the system in question to a set of 
type II-A, II-B, and II-C Cas9s to determine similarity. The final set of self-targeting instances 
found in Staphylococcus genomes on NCBI can be found in SI Appendix, Dataset S1. Strains 
were chosen for further study based on similarity of the downstream target site to the SauCas9 
PAM (3′-NNGRR(T) ) and similarity of the self-targeting system’s Cas9 to SauCas9 by blastp.  
 
Guilt-by-association search. GF genes 1 and 2 (AcrIIA13) were used to query the NCBI protein 
database with blastp to identify homologs. Each homolog found was then manually surveyed for 
neighboring genes that were not found within the genome fragment amplicons tested with the 
TXTL sfGFP assay. This approach was repeated using any neighboring proteins to further locate 
their neighbors. Only alignments with an E-value < 0.001 were considered. The search was 
ended after 10 candidate proteins were identified.  
 
gDNA extraction. To extract gDNA, 4 mL of a culture containing Staphylococcus haemolyticus 
(strains W_75 and W_139) or Staphylococcus schleiferi (strains 5909-02 and 2713-03) cells 
were grown overnight in Tryptic Soy Broth. The cultures were then pelleted and resuspended in 
500 μL of PBS. Cells were then treated with lysostaphin for 1 hr at 37°C. gDNA was then 
extracted using the Monarch gDNA Purification Kit from NEB following the manufacturer’s 
instructions. 
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Template preparation for TXTL. Each TXTL reaction contained three template DNA sources: 
a sfGFP constitutive reporter plasmid (pUC), a plasmid expressing a sgRNA targeting GFP 
(pUC) using the SauCas9 sgRNA sequence from Strutt, et al. (27), an either a plasmid expressing 
SauCas9 under an arabinose promoter (p15A) or a genomic amplicon containing the Cas9 from 
S. haemolyticus or S. schleiferi. Reactions may also contain an Acr or Acr candidate expressed 
from a Tet-repressible promoter or a genomic fragment amplicon with the naturally occurring 
sequence. The plasmid preparation for the reporter, sgRNA plasmid, and SauCas9 were as 
described in Watters, et al. (19). To prepare the Cas9 genomic amplicons, PCR of purified 
gDNA with Q5 polymerase (New England Biolabs) was performed with primers that spanned all 
of the Cas genes (SI Appendix, Table S2). Similarly, genomic fragment amplicons were prepared 
with PCR using the gDNA and primers listed in SI Appendix, Table S2. Acr candidates that were 
to be tested individually were cloned into a plasmid for use in TXTL.  
To prepare the plasmids for TXTL, a 20 mL culture of E. coli containing one of the 
plasmids was grown to high density, then isolated across five preparations using the Monarch 
Plasmid Miniprep Kit (New England Biolabs), eluting in a total of 200 μL nuclease-free H2O. 
200 μL of AMPure XP beads (Beckman Coulter) were then added to each combined miniprep 
and purified according to the manufacturer’s instructions, eluting in a final volume of 20 μL in 
nuclease-free H2O. 
All anti-CRISPR candidate amplicons and subfragments were prepared using 100 μL 
PCRs with Q5 or Phusion polymerase (New England Biolabs), under various conditions to yield 
a clear single band on an agarose gel such that the correct fragment length was greater than 95% 
of the fluorescence intensity of the lane on the gel. 100 μL of AMPure XP beads (Beckman 
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Coulter) were then added to each reaction and purified according to the manufacturer’s 
instructions, eluting in a final volume of 10 μL in nuclease-free H2O. The PCRs and purification 
of the Cas9 genomic amplicons was scaled up 5-fold. A listing of the plasmids used in the TXTL 
experiments can be found in SI Appendix, Table S4. 
 
TXTL reactions. The reactions were carried out as described in Watters, et al. (19). Briefly, 
each reaction was mixed from 9 μL of TXTL master mix, 0.125 nM of each reporter plasmid, 1 
nM of Cas9 amplicon or plasmid, 2 nM of sgRNA plasmid, 1 nM of genomic fragment amplicon 
or Acr candidate plasmid, 1 μM of IPTG, 0.5 μM of anhydrotetracycline, 0.1% arabinose, and 2 
μM of annealed oligos containing six χ sites (40). 
The reactions were run at 29°C in a TECAN Infinite Pro F200, measuring GFP (λex: 485 
nm, λem: 535 nm) fluorescence levels every three minutes for 10 hours. To plot kinetic data, the 
minimum measured fluorescence intensity was subtracted from each point on the curve (to 
compensate for early variations due to condensation on the sealing film), then the overall curve 
was normalized by the fluorescence level measured for the non-targeting negative control after 
10 hours of reporter expression. 
 
Protein purification. DNA sequences corresponding to SauCas9 and variants of AcrIIA13-15 
were cloned downstream of 10xHis tag, MBP tag and a TEV cleavage site. Each of these 
constructs were grown in Rosetta2 cells overnight in Lysogeny Broth and were subcultured in 
750 mL of Terrific Broth. After the cultures reached an OD600 of 0.6-0.8, proteins were induced 
by treatment with 0.5 mM IPTG for ~20 hrs at 16°C. Cells were then resuspended in lysis buffer 
containing 50 mM HEPES pH 7.0, 500 mM NaCl, 1 mM TCEP and 5% (v/v) glycerol and 1X 
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Roche cOmplete protease inhibitor cocktail and lysed by sonication, followed by purification 
using Ni-NTA Superflow resin (Qiagen). The eluted proteins were then cleaved with TEV 
protease overnight at 4°C while performing buffer exchange in buffer containing 250 mM NaCl. 
The cleaved proteins were further purified using Ion exchange chromatography with a linear 
NaCl gradient using Heparin HiTrap column (GE) or HiTrap Q column (GE). The protein 
samples were then concentrated and subjected to size exclusion chromatography with Superdex 
200 size exclusion column (GE). The proteins were eluted in final storage buffer containing 20 
mM HEPES pH 7.0, 200 mM KCl, 1 mM TCEP and 5% glycerol. Plasmids for expressing the 
Acrs are available on Addgene with numbers between #138281 - #138286. 
 
In vitro cleavage assays. All dsDNA cleavage assays were performed in a 1X Cleavage Buffer 
containing 20 mM HEPES-HCl, pH 7.5, 150 mM KCl, 10 mM MgCl2, 0.5 mM TCEP. sgRNA 
sequences synthesized by IDT were first refolded in 1X cleavage buffer by heating at 70°C for 5 
min then cooling to room temperature. For all the cleavage assays involving SauCas9, reaction 
components were added in the following two ways: (1) SauCas9 and Acrs were complexed 
together, followed by sequential addition of sgRNA and dsDNA. (2) SauCas9 and sgRNA were 
complexed together, followed by addition of Acrs and dsDNA target. Each step of sequential 
additions in both reactions were preceded by incubation at 37°C for 10 min. All cleavage 
reactions were then quenched on completion with 2 µL of 6X Quenching Buffer containing 30% 
glycerol, 1.2% SDS, 250 mM EDTA. Cleavage products were read using a 1% agarose gel 
prestained with SYBRGold. All DNA/RNA sequences used for biochemical assays can be found 
in SI Appendix, Table S5. 
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Electrophoretic mobility shift assays. RNA EMSAs were performed by incubating SauCas9 
and sgRNA in 1X cleavage buffer lacking MgCl2 in the presence or absence of 10-fold molar 
excess of different Acrs relative to SauCas9. The reactions were then incubated at 37°C for 10 
mins and run on 6% TBE polyacrylamide gels for 1 hr at 50V. The gels were then visualized 
using SYBRGold stain. DNA EMSAs to evaluate binding of SauCas9 RNP to dsDNA target 
were performed by incubating the reaction components described in their respective figures in 
1X cleavage buffer lacking MgCl2 at 37°C for 10 min. The dsDNA substrates used for this assay 
were synthesized as 5′ FAM labelled 34 bp DNA oligos that were annealed prior to their addition 
to the EMSA reaction. The reactions were run on 6% TBE polyacrylamide gels and visualized on 
a Typhoon imager (GE). DNA EMSAs for the binding of AcrIIA13-15 to IR DNA were 
performed by incubating 50nM IR DNA with 0, 50, 100, 151.5 or 200 nM of Acr in 1X cleavage 
buffer lacking MgCl2 at 37°C for 10 min. The completed reactions were then run on 6% TBE 
polyacrylamide gels for 1 hr at 50V and visualized with SYBRGold stain. 
Lentiviral vectors. The lentiviral vector pCF525-mTagBFP2, expressing an EF1a-driven 
polycistronic construct containing a hygromycin B resistance marker, P2A ribosomal skipping 
element, and an mTagBFP2 fluorescence marker had been cloned before (19). For stable 
lentiviral expression of AcrIIA candidates, mTagBFP2 was replaced by the gene-of-interest open 
reading frame (ORF) using custom oligonucleotide gBlocks (IDT), Gibson assembly reagents 
(NEB), and standard molecular cloning techniques. The SpyCas9 guide RNA-only lentiviral 
vector pCF820, encoding a SpyCas9 U6-sgRNA cassette and an EF1a driven, human codon 
optimized mCherry2 marker (42), was based on the pCF221 vector (36). To make the backbone 
more efficient and increase viral titers, the f1 bacteriophage origin of replication and bleomycin 
resistance marker were removed, as has previously been done for pCF525 (19). The SauCas9 
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guide RNA-only lentiviral vector pCF824, encoding an SauCas9 U6-sgRNA cassette and an 
EF1a driven, human codon optimized mCherry2 marker, was based on the pCF820 vector. The 
SauCas9 guide RNA scaffold was designed as previously reported (42), synthesized as custom 
oligonucleotides (IDT), and assembled using Gibson techniques and standard molecular cloning 
methods. A lentiviral vector referred to as pCF823, expressing an EFS driven SpyCas9-P2A-
PuroR cassette, was based on the vector pCF204 (36) by removing the f1 bacteriophage origin of 
replication and bleomycin resistance marker to increase viral titers. A lentiviral vector referred to 
as pCF825, expressing an EFS driven SauCas9-P2A-PuroR cassette, was based on the vector 
pCF823 by replacing the SpyCas9 ORF with the SauCas9 ORF from pX601 (Addgene #61591) 
(25). Vector sequences are provided in a separate file (SI Appendix, Dataset S2). Gene editing 
plasmid vectors are available on Addgene with numbers #138305 - #138319. 
Design of sgRNAs. The following spacer sequences were used for SpyCas9 sgRNAs: sgC 
(GGAGACGGAGGACGACGAACGTCTCT), sgGFP8 (GCAGGGTCAGCTTGCCGTAGG). 
The following sequences were used for SauCas9 sgRNAs: sgC 
(GGAGACGGAGGACGACGAACGTCTCT), sgGFP1 (GCAAGGGCGAGGAGCTGTTCAC). 
Mammalian cell culture. All mammalian cell cultures were maintained in a 37°C incubator at 
5% CO2. HEK293T (293FT; Thermo Fisher Scientific) human kidney cells and derivatives 
thereof were grown in Dulbecco’s Modified Eagle Medium (DMEM; Corning Cellgro, #10-013-
CV) supplemented with 10% fetal bovine serum (FBS; Seradigm #1500-500), and 100 Units/ml 
penicillin and 100 μg/ml streptomycin (100-Pen-Strep; Gibco #15140-122). HEK293T and 
HEK-RT1 cells were tested for absence of mycoplasma contamination (UC Berkeley Cell 
Culture facility) by fluorescence microscopy of methanol fixed and Hoechst 33258 (Polysciences 
#09460) stained samples. 
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Lentiviral transduction. Lentiviral particles were produced in HEK293T cells using 
polyethylenimine (PEI; Polysciences #23966) based transfection of plasmids, as previously 
described (36). In brief, lentiviral vectors were co-transfected with the lentiviral packaging 
plasmid psPAX2 (Addgene #12260) and the VSV-G envelope plasmid pMD2.G (Addgene 
#12259). Transfection reactions were assembled in reduced serum media (Opti-MEM; Gibco 
#31985-070). For lentiviral particle production on 6-well plates, 1 µg lentiviral vector, 0.5 µg 
psPAX2 and 0.25 µg pMD2.G were mixed in 0.4 mL Opti-MEM, followed by addition of 5.25 
µg PEI. After 20-30 min incubation at room temperature, the transfection reactions were 
dispersed over the HEK293T cells. Media was changed 12 hr post-transfection, and virus 
harvested at 36-48 hr post-transfection. Viral supernatants were filtered using 0.45 µm 
polyethersulfone (PES) membrane filters, diluted in cell culture media if appropriate, and added 
to target cells. Polybrene (5 µg/ml; Sigma-Aldrich) was supplemented to enhance transduction 
efficiency, if necessary.  
Gene editing inhibition assays in human cells. Candidate anti-CRISPR (Acr) proteins were 
tested in a HEK293T-based monoclonal reporter cell line called HEK-RT1 (36, 37), which 
features a doxycycline-inducible GFP reporter (43) that can be edited before doxycycline-based 
induction of its expression. To test the effect of genomic integration and expression of AcrIIA 
candidate proteins in mammalian cells, HEK-RT1 cells were stably transduced with the lentiviral 
vector pCF525 (19) encoding the various candidate proteins or mTagBFP2, and selected on 
hygromycin B as previously described (19). The resulting HEK-RT1-AcrIIA candidates and 
HEK-RT1-mTagBFP2 genome protection and editing reporter cell lines were then used to 
quantify genome editing inhibition by flow cytometry. For this, all reporter cell lines were stably 
transduced with the lentiviral vector pCF823-SpyCas9 (expressing SpyCas9-P2A-PuroR from an 
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EFS promoter) or pCF825-SauCas9 (expressing SauCas9-P2A-PuroR from an EFS promoter) 
and selected on puromycin (1.0 µg/ml). AcrIIA/mTagBFP2 and SpyCas9/SauCas9 expressing 
HEK-RT1 reporter cell lines were then stably transduced with lentiviral vectors pCF820-Spy-
sgGFP8/sgC (U6 promoter driven expression of SpyCas9-specific guide RNAs targeting GFP or 
a non-targeting recipient control, along with an EF1a driven humanized mCherry2 marker) or 
pCF824-Sau-sgGFP1/sgC (U6 promoter driven expression of SauCas9-specific guide RNAs 
targeting GFP or a non-targeting recipient control, along with an EF1a driven humanized 
mCherry2 marker). At day three post-transduction of the guide RNA vectors, anti-CRISPR 
(AcrIIA candidates, mTagBFP2) + Cas9 (SpyCas9, SauCas9) + guide RNA (Spy-sgC/sgGFP8, 
Sau-sgC/sgGFP1) expressing HEK-RT1 reporter cells were treated with doxycycline (1 µg/ml) 
for GFP reporter induction. At 24 h post-induction, transgenic GFP genome editing efficiency 
and inhibition thereof were quantified by flow cytometry (Attune NxT, Thermo Fisher 
Scientific). For guide RNA expressing samples, quantification was gated on the mCherry-
positive (lentiviral guide RNA transduced) population. Data was normalized on samples without 
guide RNA expression treated +/- doxycycline (1 µg/ml).  
Data Availability. The code for Self-Target Spacer Searcher can be found on Github at: 
https://github.com/kew222/Self-Targeting-Spacer-Searcher. All other data discussed in the paper 
will be made available to readers. 
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Figure Legends 
 
Figure 1. Identification of self-targeting Staphylococcus strains that contain active type II 
CRISPR-Cas systems. (A) Acquisition of protospacers from MGEs can result in self-targeting 
if the MGE is capable of stably integrating (e.g. prophages) or associating (e.g. plasmid) with the 
genome. (B) Overview of TXTL assay to test for Acr activity. Cas9 template DNA is combined 
with an sfGFP reporter plasmid and a plasmid expressing a single guide RNA (sgRNA) targeting 
the reporter. In the absence of Acr activity, expression of the Cas9 RNP suppresses sfGFP 
expression. In the presence of Acrs, the Cas9 RNP is inhibited, resulting in increased 
fluorescence. (C) Genomic amplicons from S. schleiferi and S. haemolyticus containing Cas9 
lower sfGFP expression with an sfGFP-targeting sgRNA, demonstrating that the natural CRISPR 
loci are active. 
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Figure 2. Identification of three new Acrs using amplicon screening and guilt-by-
association. (A) The relative level of S. schleiferi (left) or S. haemolyticus (right) Cas9 DNA-
cleavage inhibition for each fragment was measured as percentage of the GFP expression for the 
non-targeting (NT) control after subtracting the fluorescence level observed with no Acr present. 
Thus, 0% inhibition is equivalent to the GFP expression level measured with the targeting 
sgRNA, while 100% inhibition represents no reduction in the maximum GFP expression. GF5 is 
the only amplicon that exhibits Acr activity. (B) Genes found in GF5. (C) Each gene in GF5 was 
individually cloned and tested for Acr activity with TXTL and SauCas9. The 2nd gene of GF5 
(AcrIIA13) inhibits SauCas9. (D) AcrIIA13a, a homolog of AcrIIA13, is found in GF8 and is 
also able to inhibit SauCas9 in a TXTL assay. GF8, which contains AcrIIA13a, did not exhibit 
Acr activity, however. (E) Of 10 candidates chosen from a guilt-by-association search seeded by 
GF5 gene 1, candidates 1 (AcrIIA14) and 10 (AcrIIA15) were found to inhibit SauCas9 using the 
TXTL assay. All data in this figure are from single TXTL runs. 
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Figure 3. Three SauCas9 inhibitors with distinct features and activities. (A) Plot showing 
inhibition of SauCas9 cleavage activity by AcrIIA13-15 with %cleavage plotted on y-axis and 
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Acr concentration (nM) on the x-axis. (left) Plot corresponding to the cleavage assays performed 
by first complexing Cas9 and sgRNA followed by addition of Acr and DNA. (right) Plot 
corresponding to the cleavage assays performed by first complexing Cas9 with Acrs followed by 
the addition of sgRNA and target dsDNA. The plotted data is the average %cleavage activity 
from 3 independent replicates. Error bars represent average +/- sd. (B) 6% polyacrylamide gel 
showing formation of Cas9-sgRNA RNP in the presence and absence of different Acrs. Lanes 
boxed in red represent reactions where Acrs were added before the addition of sgRNA. Lanes 
boxed in blue represent reactions where Acrs were added after the addition of sgRNA. Order of 
the addition of different reaction components are shown above the boxes. (C) 6% polyacrylamide 
gel showing binding of Cas9-sgRNA RNP to either target DNA (T) or non-target DNA (NT) in 
the presence and absence of different Acrs. Lanes boxed in red represent reactions where Acrs 
were added to Cas9 before the addition of sgRNA and dsDNA. Lanes boxed in blue represent 
reactions where Acrs were added after the addition of dsDNA to Cas9-sgRNA RNP. Order of the 
addition of different reaction components are shown above the boxes. D) Agarose gels showing 
cleavage of dsDNA target by SauCas9 in the presence of increasing amounts of each Acr with 
the N-terminus removed. Reactions were performed by adding Acrs after complexing Cas9 and 
sgRNA (top panel) or prior to the addition of sgRNA (bottom panel), as indicated to the left of 
each panel. Each reaction contains 5 nM dsDNA, 100 nM SauCas9, 100 nM sgRNA, and the 
following Acr concentrations: 50 nM, 100 nM, 200 nM, 500 nM, 1000 nM and 2000 nM. 
Uncleaved and cleaved dsDNA products are indicated by green and blue arrows, respectively. 
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Figure 4. AcrIIA13-15 share an N-terminal domain that binds a set of inverted repeats 
proximal to their promoters. (A) Schematic showing the gene structure of AcrIIA13-15. The 
gene section highlighted in blue is highly conserved across the different Acrs and contains the 
conserved helix-turn-helix (HTH) motif. The C-terminal region shows high variability across the 
three Acrs. (B) Promoter proximal sequences for AcrIIA13-15 showing the presence of two sets 
of inverted repeats (IR). IR segments are highlighted in yellow with the inverted repeat sequence 
underlined. Schematic outlines hypothesis that the HTH motif within the Acrs binds to the 
promoter proximal sequence spanning inverted repeats IR1 and IR2 to self-regulate Acr 
transcription. (C) Sequence of the dsDNA substrates used for EMSAs in D and E. These 
sequences are encoded within the promoter proximal region of AcrIIA15 that were either 
synthesized in its wildtype form or mutated to serve as negative control. (D) Individually 
purified Acr proteins bind to the AcrIIA15 promoter proximal sequence containing inverted 
repeats, causing an upshift. (E) AcrIIA15 does not bind to a mutated form of the AcrIIA15 IR 
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dsDNA substrate (left panel). Removing the N-terminal domain from AcrIIA15 prevents binding 
to the wildtype (WT) IR DNA (right panel). 
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Figure 5. AcrIIA13 is a potent and selective inhibitor of SauCas9 in mammalian cells. (A) 
Schematic of a mammalian validation platform to express Cas9, sgRNAs, and an Acr protein 
from different stably integrated lentiviral vectors in human cells, to quantify the CRISPR-Cas 
genome editing inhibitory potential of the Acr candidates by flow cytometry. HEK-RT1 cells, a 
human HEK293T-based genome editing reporter cell line with a doxycycline-inducible GFP, 
were sequentially transduced with lentiviral vectors expressing Acr candidates, SauCas9 or 
SpyCas9, and guide RNAs targeting GFP or a negative control. Three days post-transduction of 
the guide RNAs, GFP expression was induced by treatment with doxycycline for 24 hours. 
Genome editing inhibition efficiency for each Acr candidate was measured as the increase in 
percentage GFP-positive cells expressing on-target guide RNAs (sgGFP, mCherry-positive), 
compared to controls. (B) Quantification of SauCas9 and SpyCas9 inhibition efficiency of 
AcrIIA13, an N-terminal truncation of AcrIIA13, and an AcrIIA13 homolog (AcrIIA13b) in 
human cells. Error bars represent the standard deviation of triplicates. sgC, sgGFP1/sgGFP8: 
negative control and GFP-targeting guide RNAs for the respective Cas9s. The data shown for 
AcrIIA13 are partially quantification of raw flow cytometry data shown in SI Appendix, Fig. S8. 
(C) Assessment of SauCas9 and SpyCas9 inhibition by AcrIIA14, an N-terminal truncation of 
AcrIIA14, AcrIIA15, and an N-terminal truncation of AcrIIA15 in human cells. The assay was 
run as described above.  
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